Despite sound science, many recent drug launches are failing. The root cause is not the data but an underinvestment in market conditioning. Cautious investors and tighter budgets mean companies are starting their educational and scientific storytelling efforts too late, failing to prepare the market adequately.

Breakthrough drugs aren't always driven by novel biological targets. Major successes like Humira or GLP-1s often succeeded through a superior modality (a humanized antibody) or a contrarian bet on a market (obesity). This shows that business and technical execution can be more critical than being the first to discover a biological mechanism.

Eli Lilly's market dominance stems from its 2018 bet on obesity drugs, a field then considered a 'non-market.' Their philosophy is that by the time a medical market is large and obvious, it's too late to invest in R&D. They prioritize investing where the science is profound, not where the market currently is.

For truly innovative therapies in poorly understood diseases, market research is misleading because a quantifiable market doesn't exist yet. The drug's success defines the patient population and reveals the true medical need, as seen with Jakafi and Gleevec.

The cell therapy Carvykti, now a multi-billion dollar product for J&J, originated from Legend Biotech in China. When initial data showing a spectacular 100% response rate was presented at ASCO in 2017, it was met with widespread skepticism. This highlights how groundbreaking innovation can emerge from unexpected regions and be initially overlooked by the established scientific community.

Turns' drug, Turn 701, shows a significant valuation disconnect. Despite demonstrating molecular responses three times better than Novartis's Symblix—a drug with a $4B+ peak sales forecast—Turns' market cap is only 1.2 times that peak sales figure. This superior efficacy in a tough-to-treat population suggests considerable remaining upside for the stock.

Successful drug launches require nailing three fundamentals. Common failures include: misjudging the patient population (epidemiology), failing to secure reimbursement and patient access, and lacking clear differentiation against the established "gold standard" treatment in physicians' minds.

The success of Revolution Medicines' direct-on RASIB in pancreatic cancer, despite significant side effects, underscores a key principle. For diseases with high unmet need, a transformative survival benefit makes a difficult side effect profile manageable and commercially viable, shifting focus to patient management rather than perfect tolerability.

Instead of focusing solely on quarterly revenue, a successful rare disease launch was measured by KPIs like the number of patients identified and the speed of early intervention. These patient-focused metrics served as leading indicators that ultimately translated into commercial success and a stronger external narrative.